WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it is joining the U.S. Government's fight against COVID-19 with a donation of 3 million tablets of the drug Resochin (chloroquine phosphate).
Resochin, a product discovered by Bayer in 1934 and indicated for prevention and treatment of malaria, also appears to have broad spectrum antiviral properties and effects on the body’s immune response. New data from initial preclinical and evolving clinical research conducted in China, while limited, shows potential for the use of Resochin in treating patients with COVID-19 infection.
Bayer in recent days has been in talks with the White House, HHS, CDC, and the FDA, offering any assistance we can provide with a focus on donating Resochin to help in the government’s efforts to combat the virus.
Currently not approved for use in the United States, Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug’s use in the U.S.
Bayer thanks the Trump administration for moving quickly to enable this donation and will continue to work closely with the administration to support its efforts in the fight against COVID-19.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.us.
Social Media Channels
- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.